IDXX vs WLYB · P/E 40, rev $2.36B vs P/E 15, rev $1.68B
IDEXX Laboratories Inc (IDXX) versus John Wiley & Sons B (WLYB) — a side-by-side from cached financials, not a winner call.
IDEXX Laboratories Inc (IDXX) is a diagnostics & research company listed on NASDAQ.
John Wiley & Sons B (WLYB) is a publishing company listed on NYSE.
Latest reported IDXX revenue for 2026-06-30 was $2.36B. Net income was $616.9M. IDXX currently screens at market cap $43.08B and trailing P/E 40.2.
Latest reported WLYB revenue for 2026-04-30 was $1.68B. Net income was $221.6M. Revenue was down 0.1% from 2025-04-30 to 2026-04-30. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
IDXX currently screens at market cap $43.08B and trailing P/E 40.2. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
Not investment advice. Open the IDXX and WLYB stock pages for the full models.
Not investment advice.